Urocanic acid isomers in patients with basal cell carcinoma and cutaneous malignant melanoma
✍ Scribed by DE Fine Olivarius; Lock-Andersen; GRØnhØJ Larsen; Wulf; Crosby; Norval
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 499 KB
- Volume
- 138
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
✦ Synopsis
Urocanic acid (UCA) is a major chromophore for ultraviolet (UV) radiation in the skin. On UV exposure, the naturally occurring trans-isomer converts to the cis-isomer in a dose-dependent manner. Accumulating evidence indicates that cis-UCA acts as an initiator of the UV-induced suppression of certain skin immune functions. This immunomodulation is recognized as an important factor in the development of skin cancer. In this study, pigmentation and UCA isomers were measured in 29 patients with previous basal cell carcinoma (BCC), 23 patients with previous cutaneous malignant melanoma (MM), and 32 healthy controls. Measurements were performed on UV-exposed (forehead, upper back) and UV non-exposed (buttock) skin. No significant differences in pigmentation percentage, total UCA concentration, relative (%) or absolute (nmol/cm2) cis-UCA concentration were observed between the groups in any of the body sites studied. The net production of cis-UCA after irradiation with a single test UV dose was evaluated. The relative production of cis-UCA following irradiation was significantly higher in both cancer groups when compared with the control group, while no significant difference was found between the BCC and the MM patients.
📜 SIMILAR VOLUMES
Background. This study was designed to determine the risk of developing malignant melanoma (MM) in patients with a history of basal cell and/or squamous cell skin cancer (BCC/SCC) and to determine whether surveillance efforts can be directed toward these patients for the detection of early MMs. Met
Several studies report coexistent or subsequent primary tumors (SPT) among patients with malignant melanoma (MM), with the rate of incidence ranging from 1.5-20% depending on the sample size and the length and completeness of follow-up. ## METHODS. The authors followed a cohort of patients with c
## Background: Carcinoma of the pancreas is the fifth leading cancer in the u.s. and has the poorest survival rate of the major malignancies. recent studies have reported an increased risk of carcinoma of the pancreas in malignant melanoma-prone kindreds and have suggested a link between malignant